Mural Oncology Plc Stock Today
| MURA Stock | 3.44 0.20 5.49% |
Performance1 of 100
| Odds Of DistressOver 63
|
Mural Oncology is trading at 3.44 as of the 17th of December 2024, a 5.49 percent decrease since the beginning of the trading day. The stock's open price was 3.64. Mural Oncology has more than 63 % chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 17th of November 2024 and ending today, the 17th of December 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 16th of November 2023 | Category Healthcare | Classification Health Care |
Mural Oncology is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 17.06 M outstanding shares of which 476.66 K shares are now shorted by private and institutional investors with about 3.85 trading days to cover. More on Mural Oncology plc
Moving together with Mural Stock
| 0.65 | DYAI | Dyadic International | PairCorr |
| 0.83 | ESPR | Esperion Therapeutics | PairCorr |
| 0.64 | BMY | Bristol Myers Squibb | PairCorr |
Moving against Mural Stock
| 0.7 | VALN | Valneva SE ADR | PairCorr |
| 0.68 | ERNA | Eterna Therapeutics | PairCorr |
| 0.49 | PFE | Pfizer Inc Fiscal Year End 4th of February 2025 | PairCorr |
| 0.46 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.46 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.4 | SLS | Sellas Life Sciences | PairCorr |
Mural Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Caroline Loew | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
| Debt LevelsMural Oncology can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Mural Oncology's financial leverage. It provides some insight into what part of Mural Oncology's total assets is financed by creditors. | ||||||||||||||||||||||||||||||||||||||||||||||
Mural Oncology plc (MURA) is traded on NASDAQ Exchange in USA. It is located in 10 Earlsfort Terrace, Dublin, Ireland, D02 T380 and employs 107 people. Mural Oncology is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 62.1 M. Mural Oncology plc conducts business under Biotechnology sector and is part of Health Care industry. The entity has 17.06 M outstanding shares of which 476.66 K shares are now shorted by private and institutional investors with about 3.85 trading days to cover.
Mural Oncology generates negative cash flow from operations
Check Mural Oncology Probability Of Bankruptcy
Ownership AllocationMural Oncology plc maintains a total of 17.06 Million outstanding shares. Over half of Mural Oncology's outstanding shares are owned by institutional investors. These institutional investors are typically referred to as corporate investors that shop for positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Mural Ownership Details
Mural Oncology Historical Income Statement
Mural Stock Against Markets
Mural Oncology Corporate Executives
Elected by the shareholders, the Mural Oncology's board of directors comprises two types of representatives: Mural Oncology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Mural. The board's role is to monitor Mural Oncology's management team and ensure that shareholders' interests are well served. Mural Oncology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Mural Oncology's outside directors are responsible for providing unbiased perspectives on the board's policies.
When determining whether Mural Oncology plc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Mural Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mural Oncology Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mural Oncology Plc Stock: Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mural Oncology plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mural Oncology. If investors know Mural will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mural Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (9.03) | Return On Assets (0.81) | Return On Equity (1.78) |
The market value of Mural Oncology plc is measured differently than its book value, which is the value of Mural that is recorded on the company's balance sheet. Investors also form their own opinion of Mural Oncology's value that differs from its market value or its book value, called intrinsic value, which is Mural Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mural Oncology's market value can be influenced by many factors that don't directly affect Mural Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mural Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mural Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mural Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.